Physician profile
Steven Olyejar
NPI 1043285448
$1,487.99
in general payments reported to CMS, 2019-2025
17 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2021: $51.92 · 2022: $42.86 · 2023: $723 · 2024: $281 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $500 · Food and Beverage: $440 · Travel and Lodging: $208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $500.00 |
| Food and Beverage | $440.36 |
| Travel and Lodging | $208.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $708.13 | 2023 | Intrabeam |
| Boston Scientific Corporation | $201.76 | 2024 | Spaceoar System |
| Focal Therapeutics, INC. | $156.57 | 2019 | |
| Abbvie INC. | $67.76 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $61.69 | 2024-2025 | |
| Genentech USA, INC. | $44.98 | 2025 | Itovebi |
| Siemens Medical Solutions USA, INC. | $42.86 | 2022 | |
| Tesaro, INC. | $39.58 | 2019 | |
| Merit Medical Systems INC | $31.73 | 2024 | Savi Scout |
| Takeda Pharmaceuticals U.S.A., INC. | $22.15 | 2019 | |
| Merck Sharp & Dohme LLC | $19.84 | 2025 | Keytruda Qlex, Keytruda |
| Tolmar, INC. | $17.52 | 2024 | |
| Gilead Sciences, INC. | $17.34 | 2021 | |
| Novocure INC. | $15.08 | 2023 | Optune |
| Janssen Biotech, INC. | $14.60 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dova Pharmaceuticals | $14.58 | 2021 | |
| Pfizer INC. | $11.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Olyejar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.